Tae Hyun Hwang

Prof. Dr. Tae Hyun Hwang


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
DBDefne Bayik
Defne Bayik
YZYadi Zhou
Yadi Zhou
CPChihyun Park
Chihyun Park
CHChangjin Hong
Changjin Hong
DVDaniel Vail
Daniel Vail
JLJustin Lathia
Justin Lathia
Myeloid-derived suppressor cells (MDSC) that block antitumor immunity are elevated in glioblastoma (GBM) patient blood and tumors. However, the distinct contributions of monocytic (mMDSC) versus granulocytic (gMDSC) subsets have yet to be determined. In mouse models of GBM, we observed that mMDSCs were enriched in the male tumors, whereas gMDSCs were elevated in the blood of females. Depletion of gMDSCs extended survival only in female mice. Using gene-expression signatures coupled with network medicine analysis, we demonstrated in preclinical models that mMDSCs could be targeted with antiproliferative agents in males, whereas gMDSC function could be inhibited by IL1β blockade in females. Analysis of patient data confirmed that proliferating mMDSCs were predominant in male tumors and that a high gMDSC/IL1β gene signature correlated with poor prognosis in female patients. These findings demonstrate that MDSC subsets differentially drive immune suppression in a sex-specific manner and can be leveraged for therapeutic intervention in GBM. Significance: Sexual dimorphism at the level of MDSC subset prevalence, localization, and gene-expression profile constitutes a therapeutic opportunity. Our results indicate that chemotherapy can be used to target mMDSCs in males, whereas IL1 pathway inhibitors can provide benefit to females via inhibition of gMDSCs. See related commentary by Gabrilovich et al., p. 1100. This article is highlighted in the In This Issue feature, p. 1079

6 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
RTRubina Tuladhar
Rubina Tuladhar
YYYunku Yeu
Yunku Yeu
JPJohn Tyler Piazza
John Tyler Piazza
ZTZhen Tan
Zhen Tan
JCJean Rene Clemenceau
Jean Rene Clemenceau
LLLawrence Lum
Lawrence Lum
The introduction of insertion-deletions (INDELs) by non-homologous end-joining (NHEJ) pathway underlies the mechanistic basis of CRISPR-Cas9-directed genome editing. Selective gene ablation using CRISPR-Cas9 is achieved by installation of a premature termination codon (PTC) from a frameshift-inducing INDEL that elicits nonsense-mediated decay (NMD) of the mutant mRNA. Here, by examining the mRNA and protein products of CRISPR targeted genes in a cell line panel with presumed gene knockouts, we detect the production of foreign mRNAs or proteins in ~50% of the cell lines. We demonstrate that these aberrant protein products stem from the introduction of INDELs that promote internal ribosomal entry, convert pseudo-mRNAs (alternatively spliced mRNAs with a PTC) into protein encoding molecules, or induce exon skipping by disruption of exon splicing enhancers (ESEs). Our results reveal challenges to manipulating gene expression outcomes using INDEL-based mutagenesis and strategies useful in mitigating their impact on intended genome-editing outcomes.

11 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SSSamaneh K. Sarvestani
Samaneh K. Sarvestani
SSSteven Signs
Steven Signs
BHBo Hu
Bo Hu
YYYunku Yeu
Yunku Yeu
HFHao Feng
Hao Feng
EHEmina Huang
Emina Huang
The pathogenesis of ulcerative colitis (UC), a major type of inflammatory bowel disease, remains unknown. No model exists that adequately recapitulates the complexity of clinical UC. Here, we take advantage of induced pluripotent stem cells (iPSCs) to develop an induced human UC-derived organoid (iHUCO) model and compared it with the induced human normal organoid model (iHNO). Notably, iHUCOs recapitulated histological and functional features of primary colitic tissues, including the absence of acidic mucus secretion and aberrant adherens junctions in the epithelial barrier both in vitro and in vivo. We demonstrate that the CXCL8/CXCR1 axis was overexpressed in iHUCO but not in iHNO. As proof-of-principle, we show that inhibition of CXCL8 receptor by the small-molecule non-competitive inhibitor repertaxin attenuated the progression of UC phenotypes in vitro and in vivo. This patient-derived organoid model, containing both epithelial and stromal compartments, will generate new insights into the underlying pathogenesis of UC while offering opportunities to tailor interventions to the individual patient.

9 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JCJae-Ho Cheong
Jae-Ho Cheong
SWSam C. Wang
Sam C. Wang
SPSunho Park
Sunho Park
MPMatthew R. Porembka
Matthew R. Porembka
ACAlana L. Christie
Alana L. Christie
THTae Hyun Hwang
Tae Hyun Hwang
Genomic profiling can provide prognostic and predictive information to guide clinical care. Biomarkers that reliably predict patient response to chemotherapy and immune checkpoint inhibition in gastric cancer are lacking. In this retrospective analysis, we use our machine learning algorithm NTriPath to identify a gastric-cancer specific 32-gene signature. Using unsupervised clustering on expression levels of these 32 genes in tumors from 567 patients, we identify four molecular subtypes that are prognostic for survival. We then built a support vector machine with linear kernel to generate a risk score that is prognostic for five-year overall survival and validate the risk score using three independent datasets. We also find that the molecular subtypes predict response to adjuvant 5-fluorouracil and platinum therapy after gastrectomy and to immune checkpoint inhibitors in patients with metastatic or recurrent disease. In sum, we show that the 32-gene signature is a promising prognostic and predictive biomarker to guide the clinical care of gastric cancer patients and should be validated using large patient cohorts in a prospective manner.

9 July 2021 in Leukemia
Verified
Journal Article
Closed access
PDF file
LSL. C. Stetson
L. C. Stetson
DBDheepa Balasubramanian
Dheepa Balasubramanian
SRSusan Pereira Ribeiro
Susan Pereira Ribeiro
TSTammy Stefan
Tammy Stefan
KGKalpana Gupta
Kalpana Gupta
DWDavid N. Wald
David N. Wald

12 May 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ZJZachary Jackson
Zachary Jackson
CHChangjin Hong
Changjin Hong
RSRobert Schauner
Robert Schauner
BDBoro Dropulic
Boro Dropulic
PCPaolo F. Caimi
Paolo F. Caimi
DWDavid N. Wald
David N. Wald
Chimeric antigen receptor T-cell (CAR-T cell) therapy directed at CD19 produces durable remissions in the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL). Nonetheless, many patients receiving CD19 CAR-T cells fail to respond for unknown reasons. To reveal changes in 4-1BB–based CD19 CAR-T cells and identify biomarkers of response, we used single-cell RNA sequencing and protein surface marker profiling of patient CAR-T cells pre- and postinfusion into patients with NHL. At the transcriptional and protein levels, we note the evolution of CAR-T cells toward a nonproliferative, highly differentiated, and exhausted state, with an enriched exhaustion profile in CAR-T cells of patients with poor response marked by TIGIT expression. Utilizing in vitro and in vivo studies, we demonstrate that TIGIT blockade alone improves the antitumor function of CAR-T cells. Altogether, we provide evidence of CAR-T cell dysfunction marked by TIGIT expression driving a poor response in patients with NHL. Significance: This is the first study investigating the mechanisms linked to CAR-T patient responses based on the sequential analysis of manufactured and infused CAR-T cells using single-cell RNA and protein expression data. Furthermore, our findings are the first to demonstrate an improvement of CAR-T cell efficacy with TIGIT inhibition alone. This article is highlighted in the In This Issue feature, p. 1825